Veloxis parts ways with CEO
William J. Polvino is stepping down from his role as CEO of biotech company Veloxis just one week after its main asset, Envarsus, was launched in the US. He will be replaced by an experienced American.
BY NIKLAS KRIGSLUND
William J. Polvino is leaving Veloxis after more than six years in charge of the biotech company as its Chief Executive Officer. He will be replaced at the helm by Craig A. Collard, who joins from a CEO position at BioMarck Pharmaceuticals, with immediate effect, the company says in a stock market release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Veloxis launches transplant drug in the US
For abonnenter
Veloxis wins Orphan Drug status
For abonnenter
Veloxis loses legal battle with FDA
For abonnenter
